Sei Investments Co. Sells 19,966 Shares of BioNTech SE Sponsored ADR $BNTX

Key Points

• Sei Investments Co. significantly reduced its holding in BioNTech SE by 86.0% during the first quarter, now owning just 3,255 shares valued at approximately $296,000.
• BioNTech's latest quarterly earnings report showed a loss of ($1.60) per share, missing estimates, despite revenues of $306.46 million, indicating a year-over-year revenue increase of 102.6%.
• Several institutions, including Probity Advisors and Mitsubishi UFJ Asset Management, have increased their stakes in BioNTech, reflecting investor interest despite mixed analyst reports, with a consensus rating of "Moderate Buy".

Sei Investments Co. lowered its holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 86.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,255 shares of the company's stock after selling 19,966 shares during the period. Sei Investments Co.'s holdings in BioNTech were worth $296,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Banque Cantonale Vaudoise purchased a new position in shares of BioNTech during the 1st quarter valued at $36,000. Costello Asset Management INC bought a new position in shares of BioNTech during the 1st quarter worth $91,000. Goodman Advisory Group LLC bought a new position in shares of BioNTech during the 1st quarter worth $105,000. Tower Research Capital LLC TRC grew its stake in shares of BioNTech by 61.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,881 shares of the company's stock worth $214,000 after acquiring an additional 713 shares during the period. Finally, Probity Advisors Inc. grew its stake in shares of BioNTech by 8.5% during the 4th quarter. Probity Advisors Inc. now owns 1,970 shares of the company's stock worth $224,000 after acquiring an additional 154 shares during the period. Hedge funds and other institutional investors own 15.52% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Citigroup reiterated a "buy" rating and set a $140.00 price target (down previously from $145.00) on shares of BioNTech in a research note on Tuesday, May 6th. Leerink Partners set a $112.00 price target on BioNTech in a research note on Monday, June 2nd. The Goldman Sachs Group started coverage on BioNTech in a research note on Thursday, May 29th. They set a "neutral" rating and a $110.00 price target for the company. Wall Street Zen raised BioNTech from a "sell" rating to a "hold" rating in a report on Saturday, June 7th. Finally, Bank of America increased their price objective on BioNTech from $126.00 to $134.00 and gave the stock a "buy" rating in a report on Tuesday, August 5th. Thirteen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $135.80.

BioNTech Price Performance

Shares of NASDAQ BNTX traded down $0.3690 during trading hours on Wednesday, reaching $111.0310. 514,074 shares of the stock traded hands, compared to its average volume of 927,743. The company's 50-day simple moving average is $109.58 and its two-hundred day simple moving average is $105.66. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a 52-week low of $81.20 and a 52-week high of $131.49. The company has a market capitalization of $26.69 billion, a P/E ratio of -69.50 and a beta of 1.23.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.41) by ($0.19). BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The company had revenue of $306.46 million for the quarter, compared to the consensus estimate of $161.26 million. During the same quarter in the previous year, the business earned ($3.36) earnings per share. BioNTech's revenue was up 102.6% compared to the same quarter last year. BioNTech has set its FY 2025 guidance at EPS. Equities research analysts forecast that BioNTech SE Sponsored ADR will post -3.88 EPS for the current year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.